AMDL Announces Teleconference to Discuss Its Second Quarter 2008 Financial Results

Saturday, August 16, 2008 General News J E 4
TUSTIN, Calif., Aug. 15 ( Inc. (Amex: ADL), a world leader in specialty pharmaceuticals withoperations in Shenzhen, Jiangxi and Jilin China, announced today its chiefexecutive officer Gary Dreher and chief financial officer Akio Ariura willhost a teleconference to discuss the Company's second quarter 2008 financialresults. The call is scheduled for Tuesday, August 19, 2008 at 1:45 p.m.Pacific Standard Time (4:45 p.m. Eastern Time).

Existing or potential investors who would like to submit questions priorto the call can do so by emailing Kristine Szarkowitz at

To access the live call, please dial (877) 360-1705 in the U.S. or(706) 902-3245 outside the U.S. and reference Conference ID# 60855707 fiveminutes before the call begins. The conference call script will also beavailable on the Investor section of the AMDL web site located at Click on "Investor Relations," then "Recent News" toaccess the Company's earnings release which was issued today, August 15, 2008,and all other accompanying financial and operating information.

About AMDL:

AMDL Inc. is a global specialty pharmaceutical company. The company isheadquartered in Tustin, California with operations in Shenzhen, Jiangxi, andJilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDLis devoted to the research, development, manufacture, and marketing ofdiagnostic, pharmaceutical, nutritional supplement, and cosmetic productscurrently in China. The company employs approximately 320 people in the U.S.and China. More information about AMDL and its products can be obtained at

About Jade Pharmaceutical:

JPI has access to the fastest growing pharmaceutical and consumer marketin the world -- China. AMDL, through its Jade subsidiaries, currently holdslicenses for 133 products that are manufactured as large volume injectionfluids, tablets and other related products. It currently manufactures over 20key generic, over-the-counter and supplemental pharmaceutical products undercertified Chinese Good Manufacturing Practice (CGMP) standards.AMDL Contact: Kristine Szarkowitz Director-Investor Relations (M) (206) 310-5323



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
NUCRYST Receives Deficiency Notice from NASDAQ
ETEX Launches Innovative Osteoinductive Orthobiolo...